FDA Approves Zeposia(R) (ozanimod), for Adults with Moderately to Severely Active Ulcerative Colitis

Zeposia, is the first and only oral sphingosine 1-phosphate (S1P) receptor modulator approved for ulcerative colitis1, represents a new way of treating this chronic immune-mediated disease2